3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
19
Carcinoma, Hepatocellular
8
Squamous Cell Carcinoma of Head and Neck
7
Melanoma
7
Lung Neoplasms
5
Neoplasms
4
Neoplasm Metastasis
4
Esophageal Neoplasms
4
Uterine Cervical Neoplasms
3
Rectal Neoplasms
3
Head and Neck Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Pathologic Complete Response
2
Pancreatic Neoplasms
2
Neoplasm, Residual
2
Hyperthermia
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Brain Neoplasms
2
Uveal Melanoma
1
Turcot syndrome
1
Small Cell Lung Carcinoma
1
Small Cell Lung Cancer Extensive Stage
1
Sarcoma
1
Radiation Pneumonitis
1
Interventions
Cyclophosphamide
6
Rituximab
3
isatuximab
2
fludarabine phosphate
2
fludarabine
2
durvalumab
2
anlotinib
2
Whole-Body Irradiation
2
Vincristine
2
Tacrolimus
2
Sunitinib
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Pemetrexed
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Lenalidomide
2
Gemcitabine
2
Doxorubicin
2
Dexamethasone
2
Cisplatin
2
Carboplatin
2
Busulfan
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
ponatinib
1
pomalidomide
1
penpulimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms by Histologic Type
×
Immunotherapy
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled